For more than a decade, CDK4/6 inhibitors have defined the treatment story of hormone receptor-positive, HER2-negative metastatic breast cancer. Palbociclib, ribociclib, and abemaciclib, combined with endocrine therapy, changed first-line expectations by extending disease control and delaying chemotherapy for many patients. Yet this progress also created a new clinical problem: what should oncologists do when patients eventually progress after CDK4/6 inhibitor-based therapy?
That post-CDK4/6 space is now becoming more structured. Instead of relying mainly on fulvestrant, aromatase inhibitor switches, or chemotherapy, clinicians increasingly have biomarker-guided endocrine options. At the center of this shift are next-generation oral selective estrogen receptor degraders, or oral SERDs, including elacestrant and imlunestrant, with camizestrant and vepdegestrant adding further momentum to the field. The result is a more precise and more complex era for post-CDK4/6 inhibitor therapy HR+ breast cancer.
Why ESR1 Mutations Became The Key Resistance Biomarker
Endocrine resistance in HR+/HER2− metastatic breast cancer is biologically heterogeneous, but ESR1 mutations have become one of the most clinically actionable mechanisms. These mutations typically emerge under the selective pressure of aromatase inhibitor therapy and allow the estrogen receptor to remain active even when estrogen signaling is therapeutically suppressed.
This matters because the standard endocrine therapies used for years were not equally effective against ESR1-mutant disease. Aromatase inhibitors are unlikely to overcome ligand-independent ER activation, and fulvestrant, although mechanistically relevant, has limitations related to intramuscular delivery, pharmacokinetics, and modest efficacy in later-line endocrine-resistant disease.
The growing use of plasma ctDNA testing has made ESR1 mutation detection more practical in routine care. Both elacestrant and imlunestrant are FDA-approved for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after progression following at least one line of endocrine therapy, and both labels rely on ESR1 mutation detection to select patients for treatment (U.S. Food and Drug Administration [FDA], 2023; FDA, 2025).
Elacestrant Established The First Oral SERD Standard
Elacestrant was the first oral SERD to move the post-CDK4/6 endocrine landscape forward. The FDA approved elacestrant for postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression after at least one line of endocrine therapy. The recommended dose is 345 mg orally once daily with food, and patients are selected based on ESR1 mutation status in a plasma specimen using an FDA-approved test (FDA, 2023).
The pivotal EMERALD trial enrolled patients with ER-positive, HER2-negative advanced or metastatic breast cancer previously treated with endocrine therapy, including prior CDK4/6 inhibitor exposure. In ESR1-mutated tumors, elacestrant improved progression-free survival compared with standard endocrine therapy. A clinically important subgroup analysis showed that patients with ESR1-mutated tumors and at least 12 months of prior endocrine therapy plus CDK4/6 inhibitor exposure had median PFS of 8.6 months with elacestrant versus 1.9 months with standard endocrine therapy (Bardia et al., 2024).
This subgroup matters because duration of benefit on prior CDK4/6 inhibitor therapy may function as a clinical marker of continued endocrine sensitivity. In other words, not every post-CDK4/6 patient should automatically move to chemotherapy or a non-endocrine strategy. For selected patients with ESR1-mutant disease and a meaningful prior endocrine response, elacestrant created an evidence-based oral endocrine option.
Imlunestrant Adds A Second Approved Oral SERD
Imlunestrant became the next major oral SERD milestone. In September 2025, the FDA approved imlunestrant for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression after at least one line of endocrine therapy. The FDA also approved the Guardant360 CDx assay as a companion diagnostic to identify ESR1 mutations for imlunestrant treatment (FDA, 2025).
The approval was based on EMBER-3, a randomized, open-label, active-controlled, multicenter trial that enrolled 874 patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer previously treated with an aromatase inhibitor either alone or with a CDK4/6 inhibitor (FDA, 2025).
EMBER-3 also tested a clinically provocative question: whether pairing a next-generation oral SERD with abemaciclib could improve outcomes after prior endocrine therapy. In the comparison of imlunestrant-abemaciclib versus imlunestrant alone, median PFS was 9.4 months versus 5.5 months, with a hazard ratio of 0.57. The benefit was reported regardless of ESR1 mutation status, although grade 3 or higher adverse events were more frequent with the combination than with imlunestrant alone (Jhaveri et al., 2024).
This does not make CDK4/6 inhibitor rechallenge universally appropriate, but it challenges the older assumption that CDK4/6 inhibition after progression has no role. The post-CDK4/6 setting may increasingly depend on how resistance developed, which CDK4/6 inhibitor was used first, how long the patient benefited, and whether a new endocrine backbone can restore ER pathway control.
Read About EMBER-3 Trial on OncoDaily
Camizestrant Moves The Field Toward Earlier Molecular Switching
Camizestrant is not only another oral SERD; it is also central to a different treatment concept: intervening at the molecular resistance stage before radiographic progression. In SERENA-2, camizestrant showed progression-free survival benefit versus fulvestrant in previously treated ER-positive advanced breast cancer, supporting further phase 3 development (Oliveira et al., 2024).
SERENA-6 then moved the field into ctDNA-adaptive treatment. In this phase 3 trial, patients receiving first-line aromatase inhibitor plus CDK4/6 inhibitor therapy were monitored for emerging ESR1 mutations. When an ESR1 mutation was detected before clinical progression, patients were switched from the aromatase inhibitor to camizestrant while continuing the CDK4/6 inhibitor. Median PFS was 16.0 months in the camizestrant-switch arm versus 9.2 months in the comparator arm, with a hazard ratio of 0.44 (Bidard et al., 2025).
This is important because it reframes ESR1 testing as more than a tool used at progression. It suggests that serial ctDNA monitoring could eventually allow oncologists to detect endocrine resistance earlier and adapt treatment before visible progression. This approach is not yet the universal standard of care, but it represents one of the most important strategic directions in HR+/HER2− metastatic breast cancer.
Read About SERENA-6 Trial on OncoDaily
Vepdegestrant Extends ER Targeting Beyond Classic SERDs
Vepdegestrant adds another mechanistic layer because it is not a traditional SERD. It is an oral PROTAC estrogen receptor degrader designed to harness the ubiquitin-proteasome system to degrade ER. In VERITAC-2, vepdegestrant improved PFS compared with fulvestrant in patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer, and its new drug application was accepted by the FDA in 2025 based on the pivotal phase 3 trial (Hamilton et al., 2025; Arvinas, 2025).
The significance of vepdegestrant is not only the clinical signal, but also the therapeutic concept. If PROTAC ER degradation proves durable and tolerable in later-stage evaluation, it may expand the endocrine-resistance toolkit beyond receptor antagonism and conventional degradation. For now, it remains part of the evolving next wave rather than an established routine option.
Read About VERITAC-2 Trial on OncoDaily
The New Post-CDK4/6 Decision Framework
The key change in post-CDK4/6 inhibitor therapy HR+ breast cancer is that treatment is no longer simply “endocrine therapy versus chemotherapy.” It is becoming a biomarker-driven sequence.
At progression, plasma ctDNA testing for ESR1 mutations is now highly relevant. If an ESR1 mutation is detected, oral SERD therapy becomes a central consideration. Elacestrant and imlunestrant are approved options in ESR1-mutated ER-positive, HER2-negative advanced or metastatic breast cancer after endocrine therapy progression (FDA, 2023; FDA, 2025).
If ESR1 is not mutated, the next step depends on other biomarkers and clinical context. PI3K/AKT pathway alterations may support AKT or PI3K pathway-directed therapy in appropriate settings. HER2-low status may create an antibody-drug conjugate option later in the sequence. Germline BRCA status, tumor burden, visceral crisis, prior toxicity, patient preference, and access also matter.
The most important principle is that post-CDK4/6 therapy should not be chosen empirically when actionable molecular information is available. ESR1, PIK3CA, AKT1, PTEN, germline BRCA1/2, and HER2-low status can all influence sequencing decisions.
What This Means For Daily Practice
For oncologists, the oral SERD era changes several routine steps. First, ESR1 mutation testing should be considered at progression after endocrine therapy, especially after aromatase inhibitor and CDK4/6 inhibitor exposure. Second, the duration of prior CDK4/6 inhibitor benefit should be interpreted clinically, because patients with longer prior endocrine sensitivity may remain appropriate candidates for endocrine sequencing. Third, oral SERDs should be integrated into broader biomarker-based planning rather than treated as isolated replacements for fulvestrant.
The convenience of oral therapy also matters. Many patients with HR+/HER2− metastatic breast cancer have already spent months or years on oral endocrine therapy and CDK4/6 inhibitors. An effective oral SERD can preserve a familiar treatment structure and may delay the need for chemotherapy in selected patients. Still, oral treatment is not automatically easier for every patient; adherence, drug-drug interactions, hepatic function, adverse events, and monitoring requirements remain important.
Remaining Questions
Several questions remain unresolved. The optimal sequencing of oral SERDs with AKT inhibitors, PI3K inhibitors, mTOR inhibitors, and antibody-drug conjugates is still evolving. The role of CDK4/6 inhibitor continuation or rechallenge remains active but unsettled. The best timing of ESR1 testing is also shifting, especially after SERENA-6 showed the potential value of detecting ESR1 mutations before clinical progression.
Another major question is how to select among multiple ER degraders. Elacestrant, imlunestrant, camizestrant, and vepdegestrant are not identical drugs. They differ in mechanism, trial populations, biomarker requirements, combination strategies, and safety profiles. Cross-trial comparisons should be avoided, and future data will need to clarify which patients benefit most from each approach.
Clinical Takeaway
The post-CDK4/6 setting in HR+/HER2− metastatic breast cancer is no longer a clinical void. It is becoming a molecularly guided treatment space where ESR1 mutations, ctDNA testing, oral SERDs, and rational combinations are changing the way clinicians think about endocrine resistance.
Elacestrant established the first approved oral SERD path for ESR1-mutated disease after endocrine therapy. Imlunestrant added another approved ER antagonist option and generated important combination data with abemaciclib. Camizestrant is pushing the field toward earlier ctDNA-guided switching, and vepdegestrant introduces a PROTAC-based ER degradation strategy.
The post-CDK4/6 era has arrived, but the central question is no longer only which drug comes next. It is which resistance mechanism is driving progression, which biomarker can be acted on, and how long endocrine-based disease control can be preserved before chemotherapy becomes necessary.